氢可酮市场规模、份额和成长分析（按形式、分销管道、应用、最终用户和地区）- 2025-2032 年产业预测

2023 年全球氢可酮市场规模价值 300.3 亿美元，预计将从 2024 年的 323.4 亿美元成长到 2032 年的 585.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 7.7%。

全球氢可酮市场是製药业的关键领域，由于慢性疼痛的增加（尤其是老龄化人口）对强效止痛药的需求不断增长，该市场专注于提供有效的疼痛管理解决方案。氢可酮在医院和安宁疗护中心等医疗机构中仍然发挥着重要作用，因为它在缓解癌症和术后恢復等疾病相关的剧烈疼痛方面发挥作用。然而，这个市场也存在挑战，包括滥用和成瘾的潜在风险，需要医疗保健提供者的谨慎管理。儘管存在这些障碍，但技术进步、创新药物配方和安宁疗护的成长凸显了市场扩张的巨大机会，最终有助于改善严重疼痛患者的生活品质。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究

氢可酮市场规模（按形式和复合年增长率） (2025-2032)

• 市场概况
• 口服锭剂
• 注射
• 胶囊
• 其他的

氢可酮市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 零售药局
• 网路药局
• 其他的

氢可酮市场规模（按应用和复合年增长率） (2025-2032)

• 市场概况
• 疼痛管理
• 止泻剂
• 感冒咳嗽药
• 其他的

氢可酮市场规模（依最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院和诊所
• 门诊手术中心
• 其他的

氢可酮市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Pfizer Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Hikma Pharmaceuticals PLC（UK）
• Mallinckrodt Pharmaceuticals（Ireland）
• Boehringer Ingelheim GmbH（Germany）
• Gerot Lannach（Austria）
• Dongbei Pharmaceutical Group Co.（China）
• Taiji Group Southwest Pharmaceutical Co.（China）
• Sun Pharmaceutical Industries Ltd.（India）
• Sanofi SA（France）
• Johnson & Johnson（USA）
• Novartis International AG（Switzerland）
• GlaxoSmithKline plc（UK）
• AstraZeneca plc（UK）
• Eli Lilly and Company（USA）
• Bayer AG（Germany）
• Roche Holding AG（Switzerland）
• Merck & Co., Inc.（USA）

结论和建议

Global Morphine Market size was valued at USD 30.03 billion in 2023 and is poised to grow from USD 32.34 billion in 2024 to USD 58.55 billion by 2032, growing at a CAGR of 7.7% during the forecast period (2025-2032).

The global morphine market, a key segment of the pharmaceutical industry, is focused on providing effective pain management solutions stemming from rising demands for potent analgesics amid increasing chronic pain conditions, particularly within the aging demographic. As morphine serves to alleviate severe pain associated with ailments like cancer and postoperative recovery, its presence in medical facilities, including hospitals and palliative care centers, remains critical. However, the market grapples with challenges such as potential abuse and addiction risk, necessitating careful management by healthcare providers. Despite these hurdles, advancements in technology, innovative drug formulations, and the growth of palliative care highlight significant opportunities for market expansion, ultimately contributing to improved quality of life for patients experiencing intense pain.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Morphine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Morphine Market Segmental Analysis

Global Morphine Market is segmented by Form, Distribution Channel, Application, End User and region. Based on Form, the market is segmented into Oral Tablets, Injection, Capsule and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on Application, the market is segmented into Pain Management, Diarrhea Suppressant, Cold & Cough Suppressant and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Morphine Market

The global morphine market is significantly influenced by the rising prevalence of chronic pain disorders. An increasing number of individuals suffering from conditions such as cancer, musculoskeletal issues, and neuropathic pain is a key market driver. According to the World Health Organization's projections from 2022, the incidence of cancer cases is expected to rise by almost 50% over the next twenty years. This surge in chronic pain cases has escalated the demand for effective analgesics, particularly morphine, thereby contributing to the overall growth of the morphine market as healthcare providers seek to offer adequate pain management solutions.

Restraints in the Global Morphine Market

The global morphine market encounters significant restraints primarily due to a stringent regulatory environment that governs opioid medications. To combat the growing epidemic of opioid misuse, addiction, and overdose, governments and healthcare authorities have implemented rigorous regulations, including restrictions on prescriptions, monitoring programs, and stringent guidelines for safe usage. While these measures aim to curtail the opioid crisis, they inadvertently pose considerable challenges for manufacturers and healthcare providers, hindering compliance and limiting access to morphine for patients who genuinely require it for medical treatment. Consequently, the balance between ensuring safety and maintaining necessary availability remains a pressing issue within the sector.

Market Trends of the Global Morphine Market

The Global Morphine market is experiencing a significant trend towards personalized pain management, with a growing emphasis on individualized treatment strategies that consider patient-specific characteristics, genetics, and unique pain profiles. This paradigm shift is fueled by advances in pharmacogenomics, which enable healthcare providers to optimize opioid therapy by identifying patients at higher risk for adverse responses. Research, including a pivotal 2022 study in the Journal of Pain and Symptom Management, highlights the potential of tailored approaches to enhance therapeutic outcomes for patients requiring morphine. As the focus on precision medicine intensifies, the demand for morphine is likely to rise, particularly among targeted patient demographics.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Morphine Market Size by Form & CAGR (2025-2032)

• Market Overview
• Oral Tablets
• Injection
• Capsule
• Others

Global Morphine Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Morphine Market Size by Application & CAGR (2025-2032)

• Market Overview
• Pain Management
• Diarrhea Suppressant
• Cold & Cough Suppressant
• Others

Global Morphine Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Global Morphine Market Size & CAGR (2025-2032)

• North America (Form, Distribution Channel, Application, End User)
  • US
  • Canada
• Europe (Form, Distribution Channel, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Form, Distribution Channel, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Form, Distribution Channel, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Form, Distribution Channel, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gerot Lannach (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dongbei Pharmaceutical Group Co. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taiji Group Southwest Pharmaceutical Co. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations